Center For Disease Analysis Foundation Announces Receipt Of An $8M Grant From Gilead Sciences To Relink Hepatitis B And C Patients To Care In The U.S.
Portfolio Pulse from Happy Mohamed
The Center for Disease Analysis Foundation (CDA Foundation) has received an $8 million grant from Gilead Sciences (NASDAQ:GILD) as part of Gilead's Relink grant program. The grant will be used to reconnect diagnosed but untreated patients with hepatitis B and C to care. Despite available treatments, many patients in the U.S. are unaware of their infection, do not seek follow-up care, or delay treatment. The Relink program aims to bridge these gaps.
July 20, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences' $8 million grant to the CDA Foundation could enhance its reputation in the healthcare sector and potentially increase demand for its hepatitis treatments.
Gilead Sciences' grant to the CDA Foundation demonstrates its commitment to addressing hepatitis B and C, which could enhance its reputation in the healthcare sector. This could potentially lead to increased demand for its hepatitis treatments, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100